GLS and hepatocellular carcinoma: Lu et al. observed that Rk1 could inhibit the progression of HepG2 HCC by inhibiting the ERK/c-Myc pathway, downregulating the expression of glutaminase GLS1, reducing the production of glutathione GSH, stimulating ROS accumulation, and inducing apoptosis (Lu et al., 2022).